VEGFA and neoplasm: Changes in VEGFR-2p expression, the main receptor target of VEGF, were observed by immunohistochemistry in 65 patients (Figure 2a); 17 of these patients showed gross tumour residual disease, 18 had minimal residual disease, and 30 had intermediate disease.